Ken Griffin Nevro Corp Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Nevro Corp stock. As of the latest transaction made, Citadel Advisors LLC holds 49,900 shares of NVRO stock, worth $211,077. This represents 0.0% of its overall portfolio holdings.

Number of Shares

49,900

Previous 26,700 86.89%

Holding current value

$211,077

Previous $224,000 24.11%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$4.71 - $10.1 $1.35 Million - $2.89 Million	286,003 Added 114.38%	536,060 $2.99 Million
Q2 2024 Aug 14, 2024	SELL	$7.96 - $13.59 $5.33 Million - $9.1 Million	-669,490 Reduced 72.81%	250,057 $2.11 Million
Q1 2024 May 15, 2024	BUY	$13.56 - $20.78 $10.7 Million - $16.5 Million	791,839 Added 620.04%	919,547 $13.3 Million
Q4 2023 Feb 14, 2024	SELL	$14.18 - $22.31 $2.98 Million - $4.69 Million	-210,212 Reduced 62.21%	127,708 $2.75 Million
Q3 2023 Nov 14, 2023	BUY	$18.22 - $25.85 $2.14 Million - $3.04 Million	117,622 Added 53.39%	337,920 $6.49 Million
Q2 2023 Aug 14, 2023	SELL	$22.62 - $39.32 $3.56 Million - $6.2 Million	-157,592 Reduced 41.7%	220,298 $5.6 Million
Q1 2023 May 15, 2023	SELL	$30.17 - $41.11 $316,332 - $431,038	-10,485 Reduced 2.7%	377,890 $13.7 Million
Q4 2022 Feb 14, 2023	BUY	$36.43 - $49.4 $5.82 Million - $7.9 Million	159,872 Added 69.96%	388,375 $15.4 Million
Q3 2022 Nov 14, 2022	SELL	$40.66 - $53.03 $1.96 Million - $2.56 Million	-48,299 Reduced 17.45%	228,503 $10.6 Million
Q2 2022 Aug 15, 2022	BUY	$40.85 - $77.67 $8.24 Million - $15.7 Million	201,605 Added 268.1%	276,802 $12.1 Million
Q1 2022 May 16, 2022	BUY	$59.95 - $92.06 $787,623 - $1.21 Million	13,138 Added 21.17%	75,197 $5.44 Million
Q4 2021 Feb 14, 2022	SELL	$81.07 - $121.29 $30.4 Million - $45.4 Million	-374,523 Reduced 85.79%	62,059 $5.03 Million
Q3 2021 Nov 15, 2021	BUY	$101.99 - $166.36 $16.2 Million - $26.5 Million	159,108 Added 57.34%	436,582 $50.8 Million
Q1 2021 May 17, 2021	SELL	$132.81 - $182.18 $5.84 Million - $8.02 Million	-44,004 Reduced 13.69%	277,474 $38.7 Million
Q4 2020 Feb 16, 2021	BUY	$138.17 - $184.34 $18.3 Million - $24.4 Million	132,181 Added 69.83%	321,478 $55.6 Million
Q3 2020 Nov 16, 2020	BUY	$114.09 - $145.51 $12.2 Million - $15.5 Million	106,636 Added 129.0%	189,297 $26.4 Million
Q2 2020 Aug 14, 2020	SELL	$89.45 - $129.85 $262,714 - $381,369	-2,937 Reduced 3.43%	82,661 $9.88 Million
Q1 2020 May 15, 2020	SELL	$70.23 - $144.31 $37.8 Million - $77.6 Million	-537,991 Reduced 86.27%	85,598 $8.56 Million
Q4 2019 Feb 14, 2020	SELL	$76.41 - $117.54 $14.3 Million - $22 Million	-187,013 Reduced 23.07%	623,589 $73.3 Million
Q3 2019 Nov 14, 2019	BUY	$61.52 - $91.1 $23.3 Million - $34.6 Million	379,456 Added 88.01%	810,602 $69.7 Million
Q2 2019 Aug 14, 2019	BUY	$58.04 - $66.99 $2.15 Million - $2.48 Million	37,086 Added 9.41%	431,146 $28 Million
Q1 2019 May 15, 2019	SELL	$35.52 - $62.62 $22.3 Million - $39.3 Million	-628,116 Reduced 61.45%	394,060 $0
Q4 2018 Feb 14, 2019	BUY	$35.43 - $56.29 $26.2 Million - $41.6 Million	738,722 Added 260.61%	1,022,176 $39.8 Million
Q3 2018 Nov 13, 2018	BUY	$44.22 - $75.47 $12.1 Million - $20.7 Million	273,895 Added 2865.31%	283,454 $0
Q2 2018 Aug 10, 2018	SELL	$72.38 - $92.5 $530,473 - $677,932	-7,329 Reduced 43.4%	9,559 $0
Q1 2018 May 11, 2018	SELL	$69.46 - $88.57 $10.1 Million - $12.9 Million	-145,846 Reduced 89.62%	16,888 $1.46 Million
Q4 2017 Feb 09, 2018	SELL	$65.94 - $93.31 $57.4 Million - $81.2 Million	-869,851 Reduced 84.24%	162,734 $11.2 Million
Q3 2017 Nov 09, 2017	BUY	$80.87 - $91.08 $83.5 Million - $94 Million	1,032,585	1,032,585 $93.8 Million

Others Institutions Holding NVRO

# of Institutions

151

Shares Held

39.3M

Call Options Held

67.9K

Put Options Held

1.59M

View Full List

About NEVRO CORP

Ticker NVRO
Exchange NYSE
Sector Healthcare
Industry Medical Devices
Shares Outstandng 35,387,800
Market Cap $150M
Description
Nevro Corp., a medical device company, provides products for patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain, as well as Senza II and Senza Omnia systems. It...

More about NVRO

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account